Clinical Trials

Despite decades of intensive genetic research and the identification of the specific fibrillin-1 mutation responsible for Marfan syndrome, clinicians still find themselves struggling to provide patients with therapies that do more than merely delay the inevitable onset of life-threatening

The development of B-SYNC is an evolution of the 2021 E-SYNC model, moving from a rare mutant protein trigger to a more universal brain protein to help a broader range of patients. In the current landscape of pediatric medicine, few diagnoses carry as much weight as diffuse midline glioma, an

The development of experimental treatments for muscular dystrophy is moving toward human trials in 2028 following encouraging results in preclinical mouse models. This milestone represents a significant leap in the application of Anthropic's Claude AI within the pharmaceutical sector, specifically

Indigenous women-led organizations like CIELO are acting as essential bridges between the medical research community and the migrant populations of Southern California. This effort is central to the California Initiative to Advance Precision Medicine (CIAPM), which allocated a $1.69 million grant

Addressing the chronic ischemia found in diabetic ulcers requires the upregulation of vascular endothelial growth factor, a process achievable through ultrasound-microbubble therapy. The skin functions as a highly sophisticated, multi-layered organ that maintains a constant state of flux, balancing

Following the successful validation of its mechanism in Phase 3 trials, bitopertin is now positioned as a potential standard of care for individuals suffering from light-induced skin hypersensitivity. For many years, patients living with erythropoietic protoporphyria have navigated a world where